24 results
8-K
STRO
Sutro Biopharma Inc
8 Jan 24
Results of Operations and Financial Condition
7:31am
.
Updated luvelta Data:
An aggregated analysis of nearly 100 women with ovarian cancer from Company’s Phase 1 program led to the following observations
8-K
EX-99.1
STRO
Sutro Biopharma Inc
1 Apr 19
Sutro Biopharma Reports Full Year 2018 Financial Results
10:22am
against folate receptor-alpha, which is highly expressed in ovarian cancer
Phase 1 dose-escalation, with dose expansion, clinical trial enrolling women
8-K
EX-99.1
STRO
Sutro Biopharma Inc
14 Aug 19
Sutro Biopharma Reports Second Quarter 2019 Financial Results
12:00am
dose-escalation, with dose expansion, clinical trial enrolling women with advanced ovarian and endometrial cancers, with initial safety data expected
8-K
EX-99.1
STRO
Sutro Biopharma Inc
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
-002 for patients with advanced platinum-resistant and refractory ovarian cancer. The women on the study are heavily pretreated and have limited
8-K
EX-99.1
STRO
Sutro Biopharma Inc
15 May 19
Sutro Biopharma Reports First Quarter 2019 Financial Results
7:00am
cancer
Phase 1 dose-escalation, with dose expansion, clinical trial enrolling women with advanced ovarian and endometrial cancers, with initial safety
8-K
EX-99.1
l3k guwqcpv22vz9
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
8-K
EX-99.1
x2x5seox9 gh0w
9 Aug 21
Business Highlights and Anticipated Second Half 2021 Milestones
7:01am
8-K
EX-99.1
idwsalum9r
7 May 21
Business Highlights and 2021 Anticipated Milestones
7:00am
8-K
EX-99.1
5uj vkkejs
18 Mar 21
Sutro Biopharma Reports Full Year 2020 Financial Results
7:00am
8-K
EX-99.1
5z21hqihakqkkj4eg
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
EX-99.2
y8uqpbu3x5
9 Sep 20
Other Events
5:23pm
8-K
EX-99.2
soxwyf8yoshngtfw
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
lnaz9 7evho
8 Jan 24
Results of Operations and Financial Condition
7:31am
DRS
EX-10.9
l72prmaew mfqwzu5
1 Jun 18
Draft registration statement
12:00am